




Supplementary Table S1. Primers for cardiomyocyte specific expression genes used in qRT-PCR


Primers	Sequence (5'-3')
TNNT2 F	GCGGGTCTGGAGACTTTCT
TNNT2 R	TTCGACCTGCAGGAGAAGTT
MYH6 F	CTTCTCACCTTAGCCCTGG
MYH6 R	GCTGCCCTCAACTACAGA
MYH7 F	CGCACCTTCTCTTGCTC
MYH7 R	GAGGACAAGGTAAACACCC
MYL7 F	GCCCAACGTGGTCTCCAA
MYL7 R	CTCCTCTCTGGGACACTC
MYL2 F	CGTCTTGTAATGAAGCCA
MYL2 R	CAACGTGTTCTCATGTTG
TNNI1 F	CCGGAAGTCGAGAGAAAACCC
TNNI1 R	TCAATGCGTATCGCTCTCA
TNNI3 F	TTTGACCTCGAGGCAAGTT
TNNI3 R	CCC GTTTCTCTCGGTG
GJA5 F	AGAGTGTGAAGAACGCCACG
GJA5 R	AACAGATGCCAAAATTCTGCT
KCNH2 F	CAACCTGGCGACCAGATAG
KCNH2 R	GGTTGGGAGAGACGTTGC
KCND3 F	GCATCCTCCGGAGATCATC
KCND3 R	CCGAGTCGTTGTCGTCCAT
KCNQ1 F	TGTCACCATGAGCAGTATG
KCNQ1 R	CCG TCCGAAGAACACCC
KCNJ2 F	CTGGCTTCGTCCTGTATGG
KCNJ2 R	GCCCACGATTGACTGGAACA
CACNA1C F	TGATCCAACGCCACCAATT
CACNA1C R	GAGGAGTCATAGGCGATTACT
RYR2 F	CATCGAACACTCTCTACGGA
RYR2 R	GGACACGCTAACTAAGATGAGGT
SERCA2a F	TTTCCTACAGTGAAAGAGGACAACC
SERCA2a R	TTCCAGGTAGTGCAGGCCACAA
SCN5A F	AGCTGGCTGATGTGATGGTC
SCN5A R	CACTGTGCCTAGGTTGCC
PPARGC1A F	GCTTCTGGTGGACTCAAGT
PPARGC1A R	GAGGGCAATCCGTCTTCATCC
TFAM F	ATGGCGTTCTCGGAAGCAT
TFAM R	TCCGCCATAAGCATCTGA
N-cadherin F	TGAGCCTGAAGCCAACCTTA
N-cadherin R	AGGTCCCTGGAGTTTCTG
Connexin 43 F	CAATCACTTGCGTGACTTC
Connexin 43 R	AAAGGCAGACTGCTCATCTC
GAPDH F	CTGGGCTACACTGAGCACC
GAPDH R	AAGTGGCTTGAGGGCAATG
Nd1 F	AACCCGCCACATCTACCATC
Nd1 R	AGGAGGCCTAGGTTGAGGTT
Nd2 F	TCAGCTAAATAAGCTATCGGGC
Nd2 R	GAGTGGGTTTGCAAGTCCT
Nd4 F	CAGCCACATAGCCCTCGTAG
Nd4 R	GCGAGGCTGCTAGAAGTCA
Nd5 F	CTGCTAACTCATGCCCAT
Nd5 R	GGAGGATCCTATTGGTGC
Nd6 F	CCTCTTTCTCTCCCCACTCA
Nd6 R	CGATGGTTTCATATCATTGGTCG

Supplementary Table S1. Continued


Primers	Sequence (5'-3')
Cox1 F	CCGACCGTTGACTATTCTCT
Cox1 R	GCTCAGACCATACTATGTA
Cox2 F	CAAACCACCTTCACCGCTACAC
Cox2 R	GGACGATGGGCATGAAACTGT
Cox3 F	AGGCATCACCCCGCTAAATC
Cox3 R	GGTGAGCTCAGGTGATTGATACTC
Atp6 F	AGCCCACTTCTTACCAAGA
Atp6 R	TACTATATGATAGGCATGTGA
D-loop F	CTCCACCATTAGCACCCAAA
D-loop R	GGTGAACACTACTGGAACGGG
RNR2 F	CCAAACCCACTCACCTTAC
RNR2 R	TCATCTTCCCTGCGGTA
β-globin F	CTGGCAGTGGAGACAGAGAAGACT
β-globin R	AGGCATCACTAAAGGCACCGAGC




Supplementary Fig. S1. Schemes and concentrations test of CYC116 treatment on H1-CMs. (A) Schematic of experimental timeline of cardiomyocyte differentiation of H1 cells and the treatment duration of CYC116 (Scheme 1: Days 14-22, Scheme 2: Days 14-26, Scheme 3: Days 14-30, Scheme 4: Days 18-30, Scheme 5: Days 22-30). (B) qRT-PCR analysis of the mRNA levels of genes related to cardiac structure, ion channels and mitochondrial functions in H1-CMs treated with 0.5 μ M, 1.5 μ M, and 5 μ M CYC116 in scheme 1 to 5. The dashed line represents vehicle control (0.1% DMSO). (C) FACS analysis of cTnt staining in H1-CMs treated with 0.5 μ M, 1.5 μ M, and 5 μ M CYC116 in scheme 1 to 5.




Supplementary Fig. S2. CYC116 improves structural maturation in H1-CMs. (A and B) Representative images (A) and statistical quantification (B) of the immunofluorescence staining of N-cadherin at Day 30 in H1-CMs treated with 5 μ M CYC116 or DMSO from Days 22-30 ($n = 10$ fields). Scale bar = 25 μ m. (C and D) Representative images (C) and statistical quantification (D) of the immunofluorescence staining of Connexin 43 at Day 30 in H1-CMs treated with 5 μ M CYC116 or DMSO from Days 22-30 ($n = 10$ fields). Scale bar = 25 μ m. (E) qRT-PCR analysis of the expression of N-cadherin and Connexin 43 at Day 30 in H1-CMs treated with 5 μ M CYC116 or DMSO from Days 22-30 ($n = 3$). Data are presented as the mean \pm SEM. ** $P < 0.01$; *** $P < 0.0001$.



Supplementary Fig. S3. CYC116 improves mitochondria maturation in H1-CMs. (A) TEM images of H1-CMs treated with DMSO or CYC116. Mit, mitochondria; Scale bars = 5 μm. (B) The relative mtDNA copy number was evaluated by the ratio of *ND1*, *ND2*, *ND4*, *ND5*, *ND6*, *Cox1*, *Cox2*, *Cox3*, *ATP6*, *D-loop*, and *RNR2* to β -globin of H1-CMs treated with DMSO or CYC116 at Day 30 (n = 3). Data are presented as the mean \pm SEM. *P < 0.05; **P < 0.01; ***P < 0.0001.



Supplementary Fig. S4. Other Aurora kinase inhibitors also increases the expression of cardiac genes in H1-CMs. qRT-PCR analysis of the mRNA levels of genes related to cardiac structure, ion channels and mitochondrial functions in H1-CMs treated with DMSO or Aurora kinase inhibitors ($n = 3$). Data are presented as the mean \pm SEM. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.



Supplementary Fig. S5. CYC116 promotes the maturation of cardiomyocytes derived from other hPSCs. (A) Transmission electron microscopy images of H9-CMs and UC013-CMs treated with DMSO or CYC116. MF, myofibrils; Z, Z-bands; Zb, Z-bodies; Mit, mitochondria. Scale bars = 1 μ m. (B) Quantitative analyses of mitochondria number per cell from TEM images of H9-CMs and UC013-CMs treated with DMSO or CYC116 ($n = 25$ cells). (C) Flow cytometry analysis of Ki67⁺ cells in CYC116-treated H9-CMs and UC013-CMs ($n = 3$). (D and E) Flow cytometry analysis of polyploidy ratio with PI staining in DMSO- or CYC116-treated H9-CMs (D) and UC013-CMs (E) ($n = 3$). Data are presented as the mean \pm SEM. ** $P < 0.01$; **** $P < 0.0001$.